Biotech: three drivers behind an extraordinary investment opportunity

Tools, techniques and knowledge prove key catalysts

Anyone who has invested in technology will be familiar with Moore's law. This eponymous theory proposed by the co-founder of Intel in 1965 stated that the processing performance of computers would double every two years due to advancements in chip design.

In the years since, it has proven uncannily accurate. However, when it comes to biotech, rates of progress have often left Moore's law for dust. Take genomic sequencing, for example. In 2003, the first whole human genome was sequenced via a laborious process that cost roughly $2.7 billion. Today, you can sequence the human genome for about $500. If Moore's law had been in play, this cost would be closer to $500,000.     Investing in biotech: Where are we now and what is the outlook? Similar stories can be found in proteomics, ribonucleic acid (RNA) science, nanotech, sensors and Cr...